© Copyright 2025 American Medical Association. All rights reserved.
This CPT® code 90619 refers to the Meningococcal conjugate vaccine, specifically designed to protect against meningococcal disease caused by serogroups A, C, W, and Y. The vaccine utilizes tetanus toxoid as a carrier protein, which aids in the immune response to the four polysaccharides present in the vaccine. Meningococcal disease is a serious infection caused by the bacterium Neisseria meningitides, which is transmitted through respiratory secretions. This infection can lead to severe health complications, including septicemia and meningitis, both of which can progress rapidly and have a high mortality rate if not treated promptly. There are 13 identified serogroups of Neisseria meningitides, with six of these being responsible for the majority of meningococcal disease cases globally. The vaccine represented by this code specifically targets serogroups A, C, W, and Y, providing crucial protection against these strains. The conjugation process used in this vaccine allows for the direct (for W and Y) and indirect (for A and C) linking of the polysaccharides to the tetanus toxoid, which enhances the immune response by producing antibodies against the capsular polysaccharides of these serogroups. Notably, this vaccine is the first of its kind approved for single-dose administration, making it a significant advancement in the prevention of invasive meningococcal disease for individuals aged 12 months and older. It is important to note that this code specifically reports the supply of the vaccine itself, while the administration of the vaccine via intramuscular injection is reported separately.
© Copyright 2025 Coding Ahead. All rights reserved.
The Meningococcal conjugate vaccine (CPT® Code 90619) is indicated for the prevention of meningococcal disease caused by serogroups A, C, W, and Y. This vaccine is particularly recommended for individuals who are at increased risk of meningococcal disease, including:
The administration of the Meningococcal conjugate vaccine involves several key procedural steps, which are as follows:
Post-procedure care for the Meningococcal conjugate vaccine includes monitoring the patient for any immediate adverse reactions, such as allergic responses or injection site reactions. Common side effects may include pain at the injection site, fever, or mild fatigue. Patients should be advised to rest and hydrate adequately following vaccination. Additionally, it is important to inform patients about the signs of serious side effects that may require immediate medical attention. Follow-up appointments may be necessary to ensure that the patient receives any additional doses required for complete vaccination, depending on the specific immunization schedule recommended for their age and health status.
| Short Descr | MENACWY-TT VACCINE IM | Medium Descr | MENACWY-TT CONJ VACC SEROGROUPS ACWY FOR IM USE | Long Descr | Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, tetanus toxoid carrier (MenACWY-TT), for intramuscular use | Status Code | Non-Covered Service | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Type of Service (TOS) | 1 - Medical Care | Berenson-Eggers TOS (BETOS) | none | MUE | 1 |
| GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | GZ | Item or service expected to be denied as not reasonable and necessary | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 95 | Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system. | GA | Waiver of liability statement issued as required by payer policy, individual case | GC | This service has been performed in part by a resident under the direction of a teaching physician | GX | Notice of liability issued, voluntary under payer policy | JZ | Zero drug amount discarded/not administered to any patient | PN | Non-excepted service provided at an off-campus, outpatient, provider-based department of a hospital | Q6 | Service furnished under a fee-for-time compensation arrangement by a substitute physician or by a substitute physical therapist furnishing outpatient physical therapy services in a health professional shortage area, a medically underserved area, or a rural area | SC | Medically necessary service or supply | SK | Member of high risk population (use only with codes for immunization) | SL | State supplied vaccine | UC | Medicaid level of care 12, as defined by each state | X1 | Continuous/broad services: for reporting services by clinicians, who provide the principal care for a patient, with no planned endpoint of the relationship; services in this category represent comprehensive care, dealing with the entire scope of patient problems, either directly or in a care coordination role; reporting clinician service examples include, but are not limited to: primary care, and clinicians providing comprehensive care to patients in addition to specialty care |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2020-04-23 | Changed | FDA approval granted on April 23, 2020. |
| 2020-01-01 | Added | First appearance in code book. |
| 2019-07-01 | Added | Code added. |
Get instant expert-level medical coding assistance.